45.53

3.01% +1.33

SpringWorks Therapeutics Inc (SWTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione

Precedente Chiudi:

$44.20

Aprire:

$44.04

Volume 24 ore:

877.94K

Capitalizzazione di mercato:

$3.37B

Reddito:

Utile/perdita netta:

$-325.10M

Rapporto P/E:

-9.3491

EPS:

-4.87

Flusso di cassa netto:

$-230.18M

1 W Prestazione:

+13.54%

1M Prestazione:

-7.46%

6M Prestazione:

+100.13%

1 anno Prestazione:

+95.83%

Intervallo 1D:

$43.44

$46.04

Portata 52W:

$18.00

$53.92

SpringWorks Therapeutics Inc Stock (SWTX) Company Profile

Nome

SpringWorks Therapeutics Inc

Settore

Healthcare (1191)

Industria

Biotechnology (688)

Telefono

203 883 9490

Indirizzo

100 Washington Boulevard, Stamford, CT

Dipendente

Cinguettio

@springworkstx

Prossima data di guadagno

2024-05-16

Ultimi documenti SEC

SWTX's Discussions on Twitter

SpringWorks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-05	Iniziato	Guggenheim	Buy
2022-12-01	Iniziato	BofA Securities	Buy
2021-01-19	Reiterato	H.C. Wainwright	Buy
2020-10-29	Reiterato	H.C. Wainwright	Buy
2020-05-05	Iniziato	Barclays	Overweight
2020-03-19	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-03-04	Downgrade	H.C. Wainwright	Buy → Neutral
2020-01-21	Reiterato	H.C. Wainwright	Buy
2019-12-04	Iniziato	H.C. Wainwright	Buy
2019-10-08	Iniziato	Cowen	Outperform
2019-10-08	Iniziato	Goldman	Buy
2019-10-08	Iniziato	JP Morgan	Overweight
2019-10-08	Iniziato	Wedbush	Outperform

Mostra tutto

SpringWorks Therapeutics Inc Borsa (SWTX) Ultime notizie

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire Inc.

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024

GlobeNewswire Inc.

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

GlobeNewswire Inc.

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

GlobeNewswire Inc.

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

GlobeNewswire Inc.

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire Inc.

SpringWorks Therapeutics Inc Azioni (SWTX) Dati Finanziari

SpringWorks Therapeutics Inc (SWTX) Reddito netto 2024

SWTX l'utile netto (TTM) è stato di -$325.10 milioni per il trimestre terminato il 2023-12-31, un -17.19% diminuire anno su anno.

SpringWorks Therapeutics Inc (SWTX) Flusso di cassa 2024

SWTX ha registrato un flusso di cassa disponibile (TTM) di -$230.18 milioni per il trimestre conclusosi con 2023-12-31, un -34.01% diminuire anno su anno.

SpringWorks Therapeutics Inc (SWTX) Utile per azione 2024

L'utile per azione (TTM) di SWTX è stato pari a -$5.15 per il trimestre terminato il 2023-12-31, un +1.15% crescita anno su anno.

SpringWorks Therapeutics Inc Azioni (SWTX) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Pichl Daniel	Chief People Officer	Feb 16 '24	Sale	50.10	15,000	751,550	45,212
Ashar Bhavesh	Chief Commercial Officer	Feb 05 '24	Sale	49.32	4,834	238,435	58,154
Pichl Daniel	Chief People Officer	Feb 02 '24	Option Exercise	27.64	16,250	449,150	71,393
Pichl Daniel	Chief People Officer	Feb 02 '24	Sale	44.32	26,181	1,160,362	45,212
Ashar Bhavesh	Chief Commercial Officer	Feb 02 '24	Sale	44.37	3,222	142,976	62,988
Hambleton Julie	Director	Jul 19 '23	Sale	29.31	2,418	70,876	4,648
Hambleton Julie	Director	Jun 20 '23	Sale	26.92	2,400	64,603	7,066